transmedТрансляционная медицинаTranslational Medicine2311-44952410-5155Almazov National Medical Research Centre, Saint Petersburg, Russia10.18705/2311-4495-2018-5-5-46-52transmed-422Research ArticleРАДИОЛОГИЯRADIOLOGY68GA-ПСМА — МЕЧЕНЫЙ БИОМАРКЕР ДЛЯ ПОЗИТРОННОЙ ЭМИССИОННОЙ ТОМОГРАФИИ (ОБЗОР ЛИТЕРАТУРЫ)68GA-PSMA — LABELED BIOMARKER FOR POSITRON EMISSION TOMOGRAPHY (LITERATURE REVIEW)ПойдаМ. Д.PoydaM. D.

лаборант-исследователь Научно-исследовательского отдела ядерной медицины и тераностики института онкологии и гематологии, клинический ординатор второго года по специальности «Радиология», ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России

a fellow of the Department of Nuclear Medicine and Theranostics

mikhailpoyda@gmail.comРыжковаД. В.RyzhkovaD. V.

д.м.н., профессор РАН, главный научный сотрудник Научно-исследовательского отдела ядерной медицины и тераностики института онкологии и гематологии, ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России

MD, PhD, professor, Researcher of the Department of Nuclear Medicine and Theranostics

Ryzhkova_DV@almazovcentre.ruСтанжевскийА. А.StanzhevskyA. A.

профессор курса радиологии кафедры лучевой диагностики и медицинской визуализации ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России; д.м.н., заместитель директора по научной работе, ФГБУ «Российский научный центр радиологии и хирургических технологий им. акад. А. М. Гранова» Минздрава России

a professor of the course of Nuclear Medicine, Almazov National Medical Research Centre, Saint Petersburg, Russia; MD, PhD, deputy director of science, Federal State Budgetary Institution “Granov Russian Scientific Centre of Radioligy and Surgical Technology” of the Ministry of Health of the Russian Federation

stanzhevsky@gmail.comФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации, Санкт-ПетербургРоссияAlmazov National Medical Research Centre, Saint PetersburgRussian Federation1 Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации, Санкт-Петербург; 2 Федеральное государственное бюджетное учреждение «Российский научный центр радиологии и хирургических технологий имени академика А. М. Гранова» Министерства здравоохранения Российской Федерации, Санкт-ПетербургРоссия1 Almazov National Medical Research Centre, Saint Petersburg 2 Federal State Budgetary Institution “Granov Russian Scientific Centre of Radioligy and Surgical Technology” of the Ministry of Health of the Russian Federation, Saint PetersburgRussian Federation201803122018554652Copyright © Пойда М.Д., Рыжкова Д.В., Станжевский А.А., 20182018Пойда М.Д., Рыжкова Д.В., Станжевский А.А.Poyda M.D., Ryzhkova D.V., Stanzhevsky A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://transmed.almazovcentre.ru/jour/article/view/422

Обзор литературы посвящен анализу диагностической эффективности совмещенной позитронной эмиссионной и компьютерной томографии (ПЭТ/КТ) с радиофармацевтическим препаратом 68Ga-ПСМА при первичном стадировании рака предстательной железы у пациентов среднего и высокого риска, определении опухолевого очага при биохимическом рецидиве заболевания и мониторингу эффективности системной и радионуклидной терапии. Перечислены причины ложноположительных и ложноотрицательных результатов ПЭТ/КТ. Сформулированы показания к выполнению процедуры. Дана краткая характеристика 68Ga-ПСМА как меченому биомаркеру неоваскуляризации при злокачественных новообразованиях других локализаций.

The review is devoted to the analysis of the diagnostic efficiency of combined positron emission and computed tomography (PET / CT) with the radiopharmaceutical 68Ga-PSMA in the initial staging of prostate cancer in middle- and high-risk patients, the determination of the tumor focus in the biochemical recurrence of the disease, and monitoring the effectiveness of systemic and radionuclide therapy. The causes of false positive and false negative results of PET / CT are listed and indications for the procedure are presented as well. 68Ga-PSMA diagnostic possibilities as a labeled biomarker of neovascularization in malignant neoplasms of other localizations are briefly described.

позитронная эмиссионная томографиярак предстательной железырадионуклидная терапия68Ga-ПСМАpositron emission tomographyprostate cancerradionuclide therapy68Ga-PSMAнетReferencesTorre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012. CA: A Cancer J Clin. 2015;65(2):87–108.Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians [Internet]. American Cancer Society; 2015 Feb 4;65(2):87–108. http://dx.doi.org/10.3322/caac.21262NCCN Guidelines: Prostate Cancer. Fort Washington, Pennsylvania: National Comprehensive Cancer Network 2018NCCN Guidelines: Prostate Cancer. Fort Washington, Pennsylvania: National Comprehensive Cancer Network 2018Israeli RS, Powell CT, Fair WR et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53(2):227-30.Israeli RS, Powell CT, Fair WR, et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53:227–230.Silver DA, Pellicer I, Fair WR et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81–5.Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.Conway RE, Petrovic N, Li Z et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol. 2006;26(14): 5310-24.Conway RE, Petrovic N, Li Z, et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol. 2006; 26: 5310-24. http://dx.doi.org/10.1128/mcb.00084-06Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528–39.Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39. http://dx.doi.org/10.1002/jcb.10661Ross JS, Sheehan CE, Fisher HA et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9(17):6357-62.Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357–62Lütje S, Heskamp S, Cornelissen AS et al. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics. 2015;5(12):1388– 401.Lütje S, Heskamp S, Cornelissen AS, et al. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics 2015;5(12):1388–401. http://dx.doi.org/10.7150/thno.13348Virgolini I, Decristoforo C, Haug A et al. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imag. 2018;45(3):471-495.Virgolini I, Decristoforo C, Haug A, et al. Current status of theranostics in prostate cancer. Eur. J. Nucl. Med. Mol. Imag. 45, 471-495. http://dx.doi.org/10.1007/s00259-017-3882-2Eder M, Schafer M, Bauder-Wust U et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23(4):688–97.Eder M, Schafer M, Bauder-Wust U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97.http://dx.doi.org/10.1021/bc200279bAfshar-Oromieh A, Malcher A, Eder M et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486-95.Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95. http://dx.doi.org/10.1007/s00259-012-2298-2Afshar-Oromieh A, Hetzheim H, Kratochwil C et al. The Theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56(11):1697–705.Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The Theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–705. http://dx.doi.org/10.2967/jnumed.115.161299Herrmann K, Bluemel C, Weineisen M et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56(6):855–61.Herrmann K, Bluemel C, Weineisen M, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56:855–61. http://dx.doi.org/10.2967/jnumed.115.156133FendlerWP, Eiber M, Beheshti M et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for PC imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014-1024.FendlerWP, Eiber M, Beheshti M, et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for PC imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014–24. http://dx.doi.org/10.1007/s00259-017-3670-zAfshar-Oromieh A, Zechmann CM, Malcher A et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20.Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20. http://dx.doi.org/10.1007/s00259-013-2525-5Afshar-Oromieh A, Avtzi E, Giesel FL et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197-209.Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209. http://dx.doi.org/10.1007/s00259-014-2949-6Eiber M, Maurer T, Souvatzoglou M et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668-74.Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–674. http://dx.doi.org/10.2967/jnumed.115.154153Eiber M, Pyka T, Okamoto S et al. 68Gallium-HBED-CC-PSMA PET compared to conventional bone scintigraphy for evaluation of bone metastases in prostate cancer patients. European Urology Supplements. 2016;15(3):e566.Eiber M, Pyka T, Okamoto S, et al. 68Gallium-HBED-CC-PSMA PET compared to conventional bone scintigraphy for evaluation of bone metastases in prostate cancer patients. European Urology Supplements. March 2016;15(3). http://dx.doi.org/10.1016/s1569-9056(16)60568-7Maurer T, Gschwend JE, Rauscher I et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2016;195(5):1436-1443.Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic Efficacy of Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging in Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2016;195(5):1436-43. http://dx.doi.org/10.1016/j.juro.2015.12.025Ceci F, Uprimny C, Nilica B et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42(8):1284-94.Ceci F, Uprimny C, Nilica B, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? EurJNuclMedMolImaging. 2015;42:1284–94. http://dx.doi.org/10.1007/s00259-015-3078-6Rauscher I, Maurer T, Fendler WP et al. (68) Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. Cancer Imaging. 2016;16(1):14.Rauscher I, Maurer T, Fendler WP, et al. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. Cancer Imaging. 2016;16:14. http://dx.doi.org/10.1186/s40644-016-0072-6Krohn T, Verburg FA, Pufe T et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42(2):210-4.Krohn T, Verburg FA, Pufe T, et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42(2):210–214. doi: 10.1007/s00259-014-2915-3Benešová M, Schäfer M, Bauder-Wüst U et al. Preclinical evaluation of a Tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56(6):914-20.Benešová M, Schäfer M, Bauder-Wüst U, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of PC. JNuclMed. 2015;56:914–920. http://dx.doi.org/10.2967/jnumed.114.147413Baum RP, Wahl RL. Third Theranostics World Congress on Gallium-68 and PRRT: Abstracts. J Nucl Med. 2015;56(Suppl 2):2A–30.Baum RP, Wahl RL. Third Theranostics World Congress on Gallium-68 and PRRT: Abstracts. J Nucl Med. 2015;56(Suppl 2):2A–30. http://dx.doi.org/10.2967/jnm565absBackhaus P, Noto B, Avramovic N et al. Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives. Eur J Nucl Med Mol Imaging. 2018;45(5):860-877.Backhaus P, Noto B, Avramovic N, et al. Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging. Springer Nature; 2018 Jan 15;45(5):860–77. http://dx.doi.org/10.1007/s00259-017-3922-yDenmeade SR, Mhaka AM, Rosen DM et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med. 2012;4(140):140ra86.Denmeade SR, Mhaka AM, Rosen DM et al. Engineering a prostate‐specific membrane antigen‐activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med 2012;4:140ra186 10.1126/scitranslmed.3003886 http://dx.doi.org/10.1126/scitranslmed.3003886Pyka T, Weirich G, Einspieler I et al. 68Ga-PSMAHBED-CC PET for differential diagnosis of suggestive lung lesions in patients with prostate cancer. J Nucl Med. 2016;57(3):367–71.Pyka T, Weirich G, Einspieler I, et al. 68Ga-PSMA-HBED-CC PET for differential diagnosis of suggestive lung lesions in patients with prostate cancer. J Nucl Med. 2016;57:367–71. http://dx.doi.org/10.2967/jnumed.115.164442Wang HL, Wang SS, Song WH et al. Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance. PLoS One. 2015;10(5):e0125924.Wang HL, Wang SS, Song WH, et al. Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance. PLoS One. 2015;10:e0125924. https://doi.org/10.1371/journal.pone.0125924Wang HL, Wang SS, Song WH, et al. Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance. PLoS One. 2015;10:e0125924. https://doi.org/10.1371/journal.pone.0125924Wang HL, Wang SS, Song WH, et al. Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance. PLoS One. 2015;10:e0125924. https://doi.org/10.1371/journal.pone.0125924

The authors declare that there are no conflicts of interest present.